

Emma Jane Dean

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2373550/publications.pdf>

Version: 2024-02-01

31
papers

1,378
citations

361413

20
h-index

454955

30
g-index

31
all docs

31
docs citations

31
times ranked

2847
citing authors

#	ARTICLE	IF	CITATIONS
1	Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. <i>Nature Medicine</i> , 2019, 25, 738-743.	30.7	202
2	Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2012, 106, 468-474.	6.4	122
3	An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib. <i>Targeted Oncology</i> , 2016, 11, 401-415.	3.6	103
4	Biomarkers of apoptosis. <i>British Journal of Cancer</i> , 2008, 99, 841-846.	6.4	101
5	First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. <i>Clinical Cancer Research</i> , 2015, 21, 3412-3419.	7.0	101
6	Phase I Trial of AEG35156 Administered as a 7-Day and 3-Day Continuous Intravenous Infusion in Patients With Advanced Refractory Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 1660-1666.	1.6	88
7	Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. <i>British Journal of Cancer</i> , 2018, 118, 1425-1433.	6.4	72
8	IAPs as a Target for Anticancer Therapy. <i>Current Cancer Drug Targets</i> , 2007, 7, 785-794.	1.6	66
9	X-linked inhibitor of apoptosis protein as a therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 1459-1471.	3.4	44
10	Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic. <i>Cancer Treatment Reviews</i> , 2007, 33, 203-212.	7.7	44
11	Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors. <i>Advances in Therapy</i> , 2015, 32, 510-522.	2.9	39
12	Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study. <i>Annals of Oncology</i> , 2010, 21, 2233-2239.	1.2	35
13	A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC. <i>British Journal of Cancer</i> , 2010, 102, 97-103.	6.4	34
14	Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer. <i>British Journal of Cancer</i> , 2012, 107, 1518-1524.	6.4	33
15	Neuroendocrine and epithelial phenotypes in small-cell lung cancer: implications for metastasis and survival in patients. <i>British Journal of Cancer</i> , 2013, 108, 1704-1711.	6.4	32
16	A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva® [®] , OSI-774) in patients with advanced solid tumors of epithelial origin. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 53-58.	2.3	29
17	Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations). <i>JCO Precision Oncology</i> , 2021, 5, 1432-1442.	3.0	29
18	Advances in the management of melanoma: targeted therapy, immunotherapy and future directions. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1437-1448.	2.4	24

#	ARTICLE	IF	CITATIONS
19	A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 6284-6294.	7.0	24
20	Selumetinib in the treatment of non-small-cell lung cancer. <i>Future Oncology</i> , 2016, 12, 2545-2560.	2.4	23
21	A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of Î±2 integrin inhibitor E7820 in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2016, 34, 329-337.	2.6	22
22	Optimization of Circulating Biomarkers of Obatoclox-Induced Cell Death in Patients with Small Cell Lung Cancer. <i>Neoplasia</i> , 2011, 13, 339-347.	5.3	19
23	A Phase Ib, Dose-Finding Study of Erlotinib in Combination With a Fixed Dose of Pertuzumab in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2012, 13, 432-441.	2.6	19
24	Biomarkers of cell death applicable to early clinical trials. <i>Experimental Cell Research</i> , 2012, 318, 1252-1259.	2.6	17
25	A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 873-883.	2.3	15
26	Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarker. <i>Cancer Biomarkers</i> , 2009, 5, 117-125.	1.7	13
27	Targeted Therapies in Epithelial Ovarian Cancer. <i>Cancers</i> , 2010, 2, 88-113.	3.7	12
28	Malignant bowel obstruction in advanced ovarian cancer. <i>Future Oncology</i> , 2017, 13, 513-521.	2.4	12
29	Novel Early Phase Clinical Trial Design in Oncology. <i>Pharmaceutical Medicine</i> , 2017, 31, 297-307.	1.9	3
30	Catastrophic lower gastrointestinal complications following spinal surgery. <i>Gut</i> , 2006, 55, 1262-1262.	12.1	1
31	Second-line treatment of postmenopausal women with advanced breast carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 613-624.	2.4	0